MTOR and prostate carcinoma: Our experimental results showed that AICAR enhances the expression of TSC1 and TSC2, whereas it reduces the expression of mTOR and MYC as well as decreases the phosphorylation of p70S6K in 22Rv1 prostate cancer cells.